Analyses using twenty-two transcripts including all three functional groups increased the predictive power of disease and successfully classified disease from controls for three of the neurodegenerative diseases AD1 (AUC 80%), AD2 (AUC 72%), ALS1 (AUC 79%), ALS2 (AUC 80%), and HD (AUC 75%) but not for PD1 (AUC 67%), PD2 (AUC 67%), FTD (AUC 70%), or the FRDA group (AUC 68%) (Figure 2d). This evidence concerns the gene ALS2 and frontotemporal dementia.